Unknown

Dataset Information

0

Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.


ABSTRACT: Background:Compared to heart failure patients with higher systolic blood pressure (SBP), those with lower SBP have a worse prognosis. To make matters worse, the latter patients often do not receive treatment with life-saving therapies that might lower blood pressure further. We examined the association between SBP and outcomes in the Prospective Comparison of angiotensin receptor-neprilysin inhibitor (ARNI) with an angiotensin-converting enzyme (ACE) inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF), as well as the effect of sacubitril/valsartan, compared with enalapril, according to baseline SBP. Methods:We analysed the effect of treatment on SBP and on the primary composite outcome (cardiovascular death or heart failure hospitalization), its components and all-cause death. We examined baseline SBP as a categorical (<110, 110 to?

SUBMITTER: Bohm M 

PROVIDER: S-EPMC6251522 | BioStudies | 2017-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5836847 | BioStudies
2018-01-01 | S-EPMC6128510 | BioStudies
2018-01-01 | S-EPMC6607477 | BioStudies
2019-01-01 | S-EPMC6801941 | BioStudies
2020-01-01 | S-EPMC7772612 | BioStudies
2019-01-01 | S-EPMC6406731 | BioStudies
2019-01-01 | S-EPMC6538576 | BioStudies
2019-01-01 | S-EPMC6989284 | BioStudies
1000-01-01 | S-EPMC5933963 | BioStudies
2020-01-01 | S-EPMC6972579 | BioStudies